Friday, April 4, 2025 4/4/2025

Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology

Award Number: R37CA229810
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology - PROJECT SUMMARY/ABSTRACT Approximately 700,000 pancreatic cysts are incidentally detected by imaging each year. Up to 70% of these radiologically-detected cysts are intraductal papillary mucinous neoplasms (IPMNs), bona fide precursor lesions to pancreatic ductal adenocarcinoma (PDAC), a malignancy with a 5-year relative survival rate of only 12%. The goal of our parent grant is to fulfill the unmet need to discover a noninvasive biomarker and imaging approach that has greater accuracy in predicting IPMN pathology than conventional radiologic and clinical features, thereby enhancing clinical decision-making and promoting more good than harm for patients at- risk to harbor or develop early PDAC. Our central hypothesis is that radiomic features extracted from preoperative CT scans will more accurately predict IPMN pathology than conventional radiologic features, both individually and in combination with a plasma-based miRNA genomic classifier (MGC). We further hypothesize that the most promising radiomic features may serve as noninvasive surrogates for underlying biological processes (which are miRNA-mediated and/or linked to mucin expression) that drive IPMN development and progression to invasion. In the two-year extension period, we plan to continue to address this goal and hypothesis by applying new artificial intelligence (AI)-based approaches and incorporating additional classes of biomarkers (blood-based and behavioral). We aim to: evaluate the value of artificial intelligence (AI)-driven CT deep learning radiomic features in predicting malignant versus benign IPMN pathology in retrospective and prospective cohorts (Aim 1), evaluate telomere length and telomerase activity in the blood as candidate molecular markers of high-grade IPMNs or early-stage PDAC (Aim 2), and use behavioral AI to predict malignant transformation among patients with a high risk to develop PDAC (Aim 3). This line of translational research has potential to foster clinically actionable information that could be used to rapidly and cost-effectively personalize care for individuals with IPMNs and ultimately reduce the burden of PDAC as a major health problem, a goal in line with the parent award and with NCI’s mission to lead, conduct, and support cancer research across the nation to advance scientific knowledge and help all people live longer, healthier lives.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 USF MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	001	6	2/12/2025	EXTENSION WITH OR WITHOUT FUNDS	$296,143
2025	2023	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 USF MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	5	2/12/2025	NON-COMPETING CONTINUATION	-$296,143
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $779,609 )
2024	2024	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 USF MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	6	8/26/2024	EXTENSION WITH OR WITHOUT FUNDS	$779,609
														Subtotal = $779,609

Issue Date FY: 2023 ( Subtotal = $653,811 )
2023	2023	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	5	7/18/2023	NON-COMPETING CONTINUATION	$653,811
														Subtotal = $653,811

Issue Date FY: 2022 ( Subtotal = $667,478 )
2022	2022	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	4	8/14/2022	NON-COMPETING CONTINUATION	$667,478
														Subtotal = $667,478

Issue Date FY: 2021 ( Subtotal = $667,793 )
2021	2021	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	3	6/8/2021	NON-COMPETING CONTINUATION	$667,793
														Subtotal = $667,793

Issue Date FY: 2020 ( Subtotal = $668,096 )
2020	2020	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	2	6/30/2020	NON-COMPETING CONTINUATION	$668,096
														Subtotal = $668,096

Issue Date FY: 2019 ( Subtotal = $704,393 )
2019	2019	H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC.	12902 MAGNOLIA DR	TAMPA	FL	33612	HILLSBOROUGH	USA	Cancer Detection and Diagnosis Research	000	1	4/10/2019	NEW	$704,393
														Subtotal = $704,393

Grand Total All Awards = $4,141,180

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology

Award Number: R37CA229810

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer